Amneal Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
AMRX$21.28+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except per share amounts)
| Years Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net revenue | $3,018,760 | $2,793,957 | $2,393,607 |
| Cost of goods sold | 1,905,452 | 1,773,519 | 1,573,042 |
| Gross profit | 1,113,308 | 1,020,438 | 820,565 |
| Selling, general and administrative | 526,827 | 476,436 | 429,675 |
| Research and development | 186,175 | 190,714 | 163,950 |
| In-process research and development impairment charges | — | — | 30,800 |
| Intellectual property legal development expenses | 7,632 | 5,845 | 3,828 |
| Restructuring and other charges | 4,208 | 2,355 | 1,749 |
| (Credit) charges related to legal matters, net | (390) | 96,692 | 1,824 |
| Other operating income | (5,240) | (930) | (15,635) |
| Operating income | 394,096 | 249,326 | 204,374 |
| Other (expense) income: | |||
| Interest expense, net | (241,091) | (258,595) | (210,629) |
| Foreign exchange gain (loss), net | 7,635 | (6,846) | 1,671 |
| Loss on refinancing | (31,365) | — | (40,805) |
| Increase in tax receivable agreement liability | (6,588) | (50,680) | (3,124) |
| Other income, net | 16,522 | 11,782 | 8,243 |
| Total other expense, net | (254,887) | (304,339) | (244,644) |
| Income (loss) before income taxes | 139,209 | (55,013) | (40,270) |
| Provision for income taxes | 11,276 | 18,863 | 8,452 |
| Net income (loss) | 127,933 | (73,876) | (48,722) |
| Less: Net income attributable to non-controlling interests | (55,876) | (43,010) | (35,271) |
| Net income (loss) attributable to Amneal Pharmaceuticals, Inc. | $72,057 | $(116,886) | $(83,993) |
| Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders: | |||
| Basic | $0.23 | $(0.38) | $(0.48) |
| Diluted | $0.22 | $(0.38) | $(0.48) |
| Weighted-average common shares outstanding: | |||
| Basic | 313,367 | 308,978 | 176,136 |
| Diluted | 324,805 | 308,978 | 176,136 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.